• Propranolol and Emotional Memory: Meta-Analysis

  2026-10-07

  Lonergan and colleagues synthesized randomized, double-blind studies examining whether Propranolol alters the long-term retention of emotional material during consolidation and reconsolidation. The meta-analysis found modest reductions in later recall and cue-elicited fear responses in healthy adults, while emphasizing that clinical translation to conditions such as PTSD remains unresolved.

• Native PAGE Context and Evidence Boundaries

  2026-10-07

  Native protein gel electrophoresis can complement biochemical research by separating proteins according to charge, size, and conformation while avoiding some denaturing conditions. This overview explains the conceptual scope of the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit, distinguishes supplier claims from published evidence, and places native PAGE alongside findings from a 2022 study of dinaciclib in VHL-deficient clear cell renal cell carcinoma.

• Gepotidacin: Reading Evidence Beyond the Mechanism

  2026-10-07

  Gepotidacin, also known as GSK2140944, represents a distinct bacterial topoisomerase strategy for antibacterial research. This article interprets its biochemical rationale, phase 2 gonorrhea evidence, resistance signals, and limitations without reducing translational science to a laboratory protocol.

• Endothelial SGK1 and Vascular Stiffening

  2026-10-06

  Zhang and colleagues identify endothelial SGK1 as a mechanistic link between mineralocorticoid–salt exposure, endothelial sodium-channel activity, actin remodeling, and vascular stiffening. By combining endothelial-specific genetics, a DOCA–salt mouse model, and human aortic endothelial-cell experiments, the study strengthens the case for SGK1 as a target for mechanistic hypertension research while defining important limits on pharmacological interpretation.

• Isochlorogenic Acid A Hydrogel: Study Evidence

  2026-10-05

  A 2026 Gels study reported a multifunctional wound dressing that combines Isochlorogenic acid A/Fe(III) co-assembled nanoparticles with an amylopectin–carboxymethyl chitosan hydrogel. The preclinical formulation showed antibacterial activity, favorable material properties, enhanced cell migration, and improved wound-repair-associated outcomes, while remaining subject to important limitations in model scope and clinical applicability.

• Cytochalasin D: Evidence, Scope and Limits

  2026-10-04

  A source-grounded overview of Cytochalasin D as an actin polymerization inhibitor, using a human corneal epithelial nanoparticle-uptake study to clarify mechanistic interpretation, evidence quality, applicability and limitations.

• Alfuzosin HCl: From Receptor Biology to Translation

  2026-10-03

  A source-grounded perspective on how Alfuzosin HCl connects α1-receptor pharmacology, lower urinary tract physiology, analytical validation, and translational study design—while distinguishing assay performance from clinical evidence.

• ISRIB and the Biology of Accelerated Forgetting

  2026-10-01

  ISRIB (trans-isomer) offers translational researchers a mechanistically grounded way to interrogate how integrated stress response signaling influences inflammation-associated memory loss. By connecting PERK–eIF2α–ATF4 biology with hippocampal forgetting, this article outlines an evidence-led strategy for ER stress research, apoptosis assay design, and neurodegenerative disease model development.

• Adiponectin, TLR4, and Cognitive Deficits in Aged Rats

  2026-10-01

  This reference study examines how adiponectin protects aged rats from splenectomy-associated cognitive impairment, linking improved Morris water maze performance to reduced TLR4/MyD88/NF-κB signaling, oxidative stress, and microglial inflammation. Its pharmacological comparison with TAK-242 and LPS strengthens the proposed pathway model while also highlighting the limits of translating adiponectin findings to other peptide hormones or cardiovascular systems.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-10-01

  This study identifies circulating soluble GPNMB as both a mechanistically active mediator of CD8+ T-cell exhaustion and a biomarker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors develop a multimodal framework with potential value for response prediction and translational patient stratification.

• Amikacin Sulfate: NTM Workflow Guide

  2026-09-30

  Build more informative NTM experiments by separating extracellular killing, intracellular activity, and granuloma-targeted delivery. This practical Amikacin guide combines concentration-aware assays, dendritic-cell uptake workflows, controls, and troubleshooting for translational research.

• GW 4869: N-SMase and Exosome Research

  2026-09-29

  GW 4869 hydrochloride hydrate is a cell-permeable, noncompetitive neutral sphingomyelinase inhibitor and sphingolipid metabolism modulator. It is widely used as an inhibitor of exosome biogenesis, but inhibitor-based reductions in extracellular vesicle signaling require viability, particle, and cargo controls.

• TAK-242 (Resatorvid) for TLR4 Inflammation

  2026-09-29

  TAK-242 (Resatorvid) enables selective interrogation of TLR4-dependent inflammation in macrophage, neuronal, and neuroinflammation models. This guide translates the reference study into practical assay design, pathway controls, optimization steps, and troubleshooting strategies.

• Anlotinib and Angiogenic Kinase Signaling

  2026-09-28

  The reference study shows that anlotinib suppresses VEGF-, PDGF-BB-, and FGF-2-driven angiogenesis by inhibiting VEGFR2, PDGFRβ, FGFR1, and their downstream ERK signaling. Its combined migration, tube formation, ex vivo vessel-sprouting, and CAM experiments provide a useful preclinical framework for studying multi-pathway angiogenesis inhibition.

• Baricitinib in PSC: From Maps to Causality

  2026-09-28

  Baricitinib (LY3009104) offers a JAK1/2 perturbation tool for testing inflammatory signaling suggested by spatial studies of primary sclerosing cholangitis. This article focuses on what spatial proteomics can—and cannot—establish, and how to interpret follow-up experiments without confusing pathway inhibition with disease proof.

8686 records 1/580 page Next 12345 下5页 Last page